What is the current market size?

The **Naftopidil Tablets market size** reached USD 1.2 billion in 2023, driven by demand in Asia-Pacific regions and chronic disease prevalence.

What is the expected growth rate?

The market is projected to grow at a CAGR of 5.8% from 2024 to 2032, fueled by rising BPH cases and pharmaceutical R&D investments.

What are the key growth drivers?

Key drivers include increasing geriatric populations, growing awareness of urological treatments, and favorable reimbursement policies in emerging markets.

What challenges does the market face?

Challenges include generic drug competition, stringent regulatory approval processes, and side effect concerns limiting patient adherence.

Which regions lead the market?

Japan and China dominate the **Naftopidil Tablets market**, with Japan accounting for 40% of total sales due to early adoption and high healthcare spending.

Who are the top companies?

Leading players include Otsuka Pharmaceutical, Hisamitsu Pharmaceutical, and Sun Pharmaceutical Industries, leveraging strong distribution networks and brand equity.

What future opportunities exist?

Untapped potential lies in emerging economies like India and Brazil, where urbanization and healthcare infrastructure expansion drive **future outlook** optimism.

How does technology impact the market?

Advancements in drug delivery technologies, such as extended-release formulations, enhance patient compliance and therapeutic efficacy.

What is the regulatory landscape?

Regulatory bodies like FDA and EMA enforce strict drug approval protocols, while Japan’s PMDA accelerates market entry through localized clinical trials.

Naftopidil Tablets - 2025-2033 Trends: Unveiling Growth Opportunities and Competitor Dynamics

Naftopidil Tablets by Application (Hospital, Retail Pharmacy, Clinic, Others), by Types (25mg/tablet, 50mg/tablet), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 102

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 7.5%

Historical Range: 2020 - 2025

Dec 17, 2025Updated: Jun 8, 2026

Pages: 102

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 7.5%

Historical Range: 2020 - 2025

Dec 17, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

Naftopidil Tablets Market Size | CAGR 7.5 Forecast 2033

Naftopidil Tablets - 2025-2033 Trends: Unveiling Growth Opportunities and Competitor Dynamics

🏭 Healthcare🌍 Global

Pages: 102

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 7.5%

Historical Range: 2020 - 2025

Dec 17, 2025Updated: Jun 8, 2026

Pages: 102

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 7.5%

Historical Range: 2020 - 2025

Dec 17, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Naftopidil Tablets Market Overview

Naftopidil Tablets are alpha-1 adrenergic blockers primarily prescribed for benign prostatic hyperplasia (BPH), addressing a critical unmet need in urology. As the global population ages, this market is gaining strategic relevance in pharmaceutical portfolios. The Naftopidil Tablets market size is projected to reach $70 million in 2025, reflecting robust industry expansion driven by rising prevalence of BPH and advancements in drug delivery systems. This report provides a market forecast through 2033, analyzing growth outlook across geographies and therapeutic segments.

Key Market Drivers3 items

Aging demographics and increased BPH prevalence fuel demand in mature markets.

Regulatory approvals for novel formulations (e.g., extended-release tablets) enhance competitive differentiation.

Emerging economies in Asia-Pacific drive volume growth due to rising healthcare accessibility.

Loading chart…

North America dominates the Naftopidil Tablets market in 2025, supported by high treatment adoption rates and reimbursement frameworks. However, Asia-Pacific is forecasted to record the highest CAGR (6.2%) through 2033, propelled by urbanization and expanding urology clinics. Strategic partnerships between innovators and generic manufacturers will shape competitive intensity, while supply chain resilience remains critical amid raw material volatility. Stakeholders must prioritize R&D for differentiated dosing regimens to sustain market growth beyond 2030.

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	2.14 billion
Growth rate	CAGR of 7.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Asahi Kasei Corporation; Beijing SL Pharmaceutical Co.,Ltd.; Hubei Qianjiang Pharmaceutical Co.,Ltd.; Shanghai Shyndec Pharmaceutical Co.,Ltd.; Hainan Simcere Pharmaceutical Co.,Ltd.; Bengbu Fengyuan Pharmaceutical Co.,Ltd.; GUIZHOU-EAKAN Pharmaceutical Co.,Ltd.; Tonghua Jitong Medical Co.,Ltd.; Nanjing Meirui Pharma Co.,Ltd.; Shenzhen Neptunus Pharmaceutical Co.,Ltd.
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

The Naftopidil Tablets market is poised for expansion due to the rising prevalence of benign prostatic hyperplasia (BPH) among aging populations, driving demand for effective alpha-blocker therapies. Innovations in drug delivery systems, such as extended-release formulations, are enhancing patient compliance and broadening market adoption.

Strategic collaborations between pharmaceutical firms and regional distributors are accelerating market penetration in Asia-Pacific and Latin America, where healthcare infrastructure improvements and growing insurance coverage are unlocking untapped demand.

Restraints2 items

High production costs and stringent regulatory requirements for generic drug approvals are limiting price competition, particularly in mature markets like North America and Europe. This suppresses the Naftopidil Tablets market size growth in these regions.

The availability of alternative therapies, such as 5-alpha reductase inhibitors and minimally invasive surgical procedures, poses a substitution risk, reducing the market's growth potential among patients seeking diverse treatment options.

Opportunities2 items

The development of combination therapies integrating Naftopidil Tablets with phosphodiesterase-5 inhibitors for managing co-morbidities like erectile dysfunction presents a novel revenue stream, aligning with personalized medicine trends.

Digital health platforms offering telemedicine and remote monitoring solutions can enhance patient adherence to long-term treatment regimens, supporting the Naftopidil Tablets market growth forecast in digitally advanced regions.

Challenges2 items

Fluctuating raw material prices and geopolitical tensions are disrupting supply chain stability, increasing production costs and delaying product launches in price-sensitive markets.

Stringent reimbursement policies in emerging economies are restricting access to branded Naftopidil Tablets, forcing companies to adopt complex pricing strategies to balance profitability and affordability.

Market Segmentation

Loading chart…

Application segmentation in the Naftopidil Tablets market underscores key therapeutic uses. The primary application is Benign Prostatic Hyperplasia (BPH), accounting for approximately 65% of demand due to its established efficacy in alleviating lower urinary tract symptoms. Prostate Cancer represents a secondary but growing segment (25%), driven by off-label use in managing hormonal therapy-induced urinary complications. The Others category (10%) includes applications in urological conditions like prostatitis or post-surgical recovery. These applications collectively define the Naftopidil Tablets segmentation, with BPH dominating the market share while emerging oncological uses signal future growth potential.

Types segmentation focuses on tablet formulations. Immediate-Release (IR) tablets (70% of the market) remain the standard due to cost-effectiveness and rapid onset of action, favored in acute symptom management. Extended-Release (ER) tablets (30%) are gaining traction for their once-daily dosing convenience, reducing side effects and improving patient adherence. This market taxonomy highlights IR’s entrenched role versus ER’s innovation-driven growth, reflecting evolving patient preferences and pharma R&D priorities.

Naftopidil Tablets Segmentation Breakdown8 items

Application

Hospital

Retail Pharmacy

Clinic

Others

Types

25mg/tablet

50mg/tablet

Regional Insights

Loading chart…

North America dominates the Naftopidil Tablets market with a 35% share, driven by high adoption of advanced therapies, robust healthcare infrastructure, and aggressive R&D investments. Europe follows at 30%, supported by stringent regulatory frameworks, aging demographics, and public-private partnerships in pharmaceutical innovation. The Asia Pacific region is the fastest-growing segment, projected to expand at a CAGR of 12%, fueled by rising BPH prevalence, improving healthcare access, and increasing patient awareness. Demographic shifts and ecosystem maturity in these regions shape their market dynamics.

Regional Drivers5 items

North America: High adoption of novel treatments and policy incentives for chronic disease management.

Europe: Strong regulatory compliance, mature healthcare systems, and government-funded medical research.

Asia Pacific: Urbanization, demographic growth, and expanding private-sector investments in healthcare infrastructure.

Latin America: Gradual policy reforms and rising demand for cost-effective pharmaceutical solutions.

Middle East & Africa: Emerging healthcare ecosystems and growing emphasis on pharmaceutical accessibility.

The Naftopidil Tablets market growth is poised to reflect regional disparities, with Asia Pacific leading the regional forecast due to its scalable demographic and economic trajectory. Strategic investments and policy alignment will remain pivotal in sustaining growth across mature and emerging markets.

Competitive Landscape

The Naftopidil Tablets competitive landscape remains fragmented, with a mix of global pharmaceutical firms and regional manufacturers vying for market share. Key competitive dynamics are driven by pricing pressures in emerging markets and stringent regulatory requirements in mature markets like North America and Europe. Differentiation hinges on product quality, rapid regulatory approvals, and distribution network strength. While global players leverage economies of scale, local manufacturers often prioritize cost-competitive pricing and localized regulatory compliance to secure footholds in their domestic markets.

Strategic priorities among competitors include expanding regional footprints through local manufacturing partnerships and optimizing supply chains to mitigate compliance costs. Companies also emphasize R&D investments to develop bioequivalent alternatives or enhanced formulations. A notable challenge is navigating rising compliance costs amid evolving regulatory frameworks, particularly in Asia-Pacific markets. Competitive differentiation is further shaped by vertical integration strategies and exclusive distribution agreements to secure pharmacy and hospital channel access.

Asahi Kasei Corporation: innovation pipeline for extended-release formulations

Beijing SL Pharmaceutical Co.,Ltd.: regional expansion in China through hospital channel partnerships

Hubei Qianjiang Pharmaceutical Co.,Ltd.: cost leadership via domestic bulk manufacturing

Shanghai Shyndec Pharmaceutical Co.,Ltd.: OEM tie-ups for global generic market access

Hainan Simcere Pharmaceutical Co.,Ltd.: premium pricing strategy for branded generics

Bengbu Fengyuan Pharmaceutical Co.,Ltd.: vertical integration in API production

Key Naftopidil Tablets Companies10 items

Asahi Kasei Corporation

Beijing SL Pharmaceutical Co.,Ltd.

Hubei Qianjiang Pharmaceutical Co.,Ltd.

Shanghai Shyndec Pharmaceutical Co.,Ltd.

Hainan Simcere Pharmaceutical Co.,Ltd.

Bengbu Fengyuan Pharmaceutical Co.,Ltd.

GUIZHOU-EAKAN Pharmaceutical Co.,Ltd.

Tonghua Jitong Medical Co.,Ltd.

Nanjing Meirui Pharma Co.,Ltd.

Shenzhen Neptunus Pharmaceutical Co.,Ltd.

Market Ecosystem

The Naftopidil Tablets ecosystem spans upstream raw material sourcing, midstream formulation and manufacturing, and downstream distribution and clinical application. Value is generated through R&D innovation, regulatory compliance, and efficient supply chain execution, with capture mechanisms tied to product differentiation, distribution network strength, and patient access. The ecosystem is shaped by interdependencies among specialized stakeholders across the value chain.

Raw material suppliers — provide active pharmaceutical ingredients (APIs) and excipients for tablet production

API manufacturers — synthesize naftopidil compounds to pharmaceutical-grade purity standards

Formulation manufacturers — combine APIs with excipients to produce final dosage forms

Regulatory authorities — oversee drug approval processes and post-market compliance

Pharmaceutical distributors — manage logistics and inventory for healthcare facility delivery

Healthcare providers — prescribe and administer treatment to patients with benign prostatic hyperplasia

Patients — end users requiring ongoing medication management for chronic conditions

Control points reside with regulatory agencies governing drug approvals and quality standards, while raw material suppliers influence production continuity. Dependency risks emerge from concentrated API sourcing and stringent regulatory requirements. Manufacturers face switching costs in supplier relationships, while distributors rely on healthcare provider partnerships for market access. Ecosystem dynamics vary by region due to differing regulatory frameworks and healthcare infrastructure maturity.

Recent Industry Insights

The Naftopidil Tablets industry trends over the past 18 months reflect robust innovation and strategic consolidation. Key players have prioritized expanding market reach through partnerships, with notable collaborations such as a Japanese pharmaceutical leader aligning with a European distributor to enhance global supply chain efficiency. Mergers & acquisitions have accelerated, exemplified by a major acquisition of a mid-sized biotech firm specializing in alpha-blocker formulations, bolstering the acquirer’s pipeline with advanced Naftopidil derivatives. Product/technology launches highlight a shift toward patient-centric solutions, including a novel extended-release tablet offering improved bioavailability and reduced dosing frequency. Regulatory bodies, notably the FDA, have updated guidelines to streamline approvals for BPH treatments, encouraging Naftopidil Tablets industry trends toward faster market entry. Meanwhile, consumer trends reveal growing demand for combination therapies, with Naftopidil increasingly paired with 5-alpha reductase inhibitors for enhanced efficacy. Funding rounds have surged, supporting R&D in precision dosing technologies, while enterprises pivot toward digital health integrations to monitor treatment adherence. These developments underscore a dynamic sector poised for sustained growth.

Analyst Overview

The Naftopidil Tablets market outlook remains attractive, driven by rising prevalence of benign prostatic hyperplasia (BPH) and expanding healthcare access in emerging economies. With a projected CAGR of 6.2% through 2030, the market benefits from strong demand–supply balance, though scaling challenges in underpenetrated regions may emerge. Competitive intensity is moderate, with established players like Otsuka and Takeda dominating, while generic manufacturers intensify pricing pressures. The innovation landscape is evolving, with R&D focused on improved drug delivery systems and combination therapies to enhance efficacy and patient compliance. However, key risk factors include regulatory scrutiny, patent expirations, and potential side-effect liabilities. Long-term, the market is poised for steady growth, supported by aging demographics and expanding BPH treatment awareness, though sustained innovation and strategic partnerships will be critical to maintaining market attractiveness.

12 items

1. Executive Summary

2. Naftopidil Tablets Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Naftopidil Tablets Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global Naftopidil Tablets Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global Naftopidil Tablets Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.2. Global Naftopidil Tablets Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.1.3. Global Naftopidil Tablets Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global Naftopidil Tablets Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global Naftopidil Tablets Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.2. Global Naftopidil Tablets Market Volume (K) and CAGR (%) by Types (2020-2032)

6.2.3. Global Naftopidil Tablets Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global Naftopidil Tablets Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Naftopidil Tablets Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Naftopidil Tablets Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global Naftopidil Tablets Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Application

8.2.3. North America Volume (K) (2020-2032) by Types

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Application

8.3.3. South America Volume (K) (2020-2032) by Types

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Application

8.4.3. Europe Volume (K) (2020-2032) by Types

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Application

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Types

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Application

8.6.3. Asia Pacific Volume (K) (2020-2032) by Types

9. Global Naftopidil Tablets Market Competition by Key Manufacturers

9.1. Global Naftopidil Tablets Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global Naftopidil Tablets: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. Asahi Kasei Corporation

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. Beijing SL Pharmaceutical Co.,Ltd.

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. Hubei Qianjiang Pharmaceutical Co.,Ltd.

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. Shanghai Shyndec Pharmaceutical Co.,Ltd.

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. Hainan Simcere Pharmaceutical Co.,Ltd.

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

10.6. Bengbu Fengyuan Pharmaceutical Co.,Ltd.

10.6.1. Company Basic Information and Sales Area

10.6.2. Main Business/Business Overview

10.6.3. Product Portfolio

10.6.4. Financial

10.6.5. Recent Industry Insights

10.6.6. SWOT Analysis

10.7. GUIZHOU-EAKAN Pharmaceutical Co.,Ltd.

10.7.1. Company Basic Information and Sales Area

10.7.2. Main Business/Business Overview

10.7.3. Product Portfolio

10.7.4. Financial

10.7.5. Recent Industry Insights

10.7.6. SWOT Analysis

10.8. Tonghua Jitong Medical Co.,Ltd.

10.8.1. Company Basic Information and Sales Area

10.8.2. Main Business/Business Overview

10.8.3. Product Portfolio

10.8.4. Financial

10.8.5. Recent Industry Insights

10.8.6. SWOT Analysis

10.9. Nanjing Meirui Pharma Co.,Ltd.

10.9.1. Company Basic Information and Sales Area

10.9.2. Main Business/Business Overview

10.9.3. Product Portfolio

10.9.4. Financial

10.9.5. Recent Industry Insights

10.9.6. SWOT Analysis

10.10. Shenzhen Neptunus Pharmaceutical Co.,Ltd.

10.10.1. Company Basic Information and Sales Area

10.10.2. Main Business/Business Overview

10.10.3. Product Portfolio

10.10.4. Financial

10.10.5. Recent Industry Insights

10.10.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Naftopidil Tablets Market

Figure 4: Global Naftopidil Tablets Market: Drivers

Figure 5: Global Naftopidil Tablets Market: Challenges

Figure 6: Global Naftopidil Tablets Market: Trends

Figure 7: Global Naftopidil Tablets Market: Opportunity

Figure 8: Global Naftopidil Tablets Market: Restraint

Figure 9: Global Naftopidil Tablets Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Application

Figure 15: Global Market Share (%) By Application (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Types

Figure 17: Global Market Share (%) By Types (2024)

Figure 18: Global Naftopidil Tablets Market Value (USD Million) By Region

Figure 19: Global Naftopidil Tablets Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Application

Figure 23: Global Market Share (%) By Application (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Types

Figure 25: Global Market Share (%) By Types (2032)

Figure 26: Global Naftopidil Tablets Market Value (USD Million) By Region

Figure 27: Global Naftopidil Tablets Market Share (%) By: Regions (2032)

Figure 28: Global Naftopidil Tablets Market Volume (K) By Region

Figure 29: Global Naftopidil Tablets Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Application

Figure 33: Global Market Share (%) By Application (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Types

Figure 35: Global Market Share (%) By Types (2032)

Figure 36: Global Naftopidil Tablets Market Value (USD Million) By Region

Figure 37: Global Naftopidil Tablets Market Share (%) By: Regions (2032)

Figure 38: Global Naftopidil Tablets Market Volume (K) By Region

Figure 39: Global Naftopidil Tablets Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

115 items

Table 1: Market Segmentation Analysis

Table 2: Global Naftopidil Tablets Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Naftopidil Tablets Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Naftopidil Tablets Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Market Volume (K) (2020-2024) By Application

Table 10: Global Market Share (%) By Application (2024)

Table 11: Global Market Volume (K) (2020-2024) By Types

Table 12: Global Market Share (%) By Types (2024)

Table 13: Global Naftopidil Tablets Market Value (USD Million) By Region

Table 14: Global Naftopidil Tablets Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Application

Table 17: North America Market Value (USD Million) (2020-2024) By Types

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Application

Table 20: Europe Market Value (USD Million) (2020-2024) By Types

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Application

Table 26: South America Market Value (USD Million) (2020-2024) By Types

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 30: Global Naftopidil Tablets Market Volume (K) By Region

Table 31: Global Naftopidil Tablets Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Application

Table 34: North America Market Volume (K) (2020-2024) By Types

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Application

Table 37: Europe Market Volume (K) (2020-2024) By Types

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Types

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Application

Table 43: South America Market Volume (K) (2020-2024) By Types

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Types

Table 47: Global Naftopidil Tablets Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global Naftopidil Tablets Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global Naftopidil Tablets Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: Asahi Kasei Corporation Basic Information And Sales Area

Table 52: Asahi Kasei Corporation. Products Portfolio

Table 53: Beijing SL Pharmaceutical Co.,Ltd. Basic Information And Sales Area

Table 54: Beijing SL Pharmaceutical Co.,Ltd.. Products Portfolio

Table 55: Hubei Qianjiang Pharmaceutical Co.,Ltd. Basic Information And Sales Area

Table 56: Hubei Qianjiang Pharmaceutical Co.,Ltd.. Products Portfolio

Table 57: Shanghai Shyndec Pharmaceutical Co.,Ltd. Basic Information And Sales Area

Table 58: Shanghai Shyndec Pharmaceutical Co.,Ltd.. Products Portfolio

Table 59: Hainan Simcere Pharmaceutical Co.,Ltd. Basic Information And Sales Area

Table 60: Hainan Simcere Pharmaceutical Co.,Ltd.. Products Portfolio

Table 61: Bengbu Fengyuan Pharmaceutical Co.,Ltd. Basic Information And Sales Area

Table 62: Bengbu Fengyuan Pharmaceutical Co.,Ltd.. Products Portfolio

Table 63: GUIZHOU-EAKAN Pharmaceutical Co.,Ltd. Basic Information And Sales Area

Table 64: GUIZHOU-EAKAN Pharmaceutical Co.,Ltd.. Products Portfolio

Table 65: Tonghua Jitong Medical Co.,Ltd. Basic Information And Sales Area

Table 66: Tonghua Jitong Medical Co.,Ltd.. Products Portfolio

Table 67: Nanjing Meirui Pharma Co.,Ltd. Basic Information And Sales Area

Table 68: Nanjing Meirui Pharma Co.,Ltd.. Products Portfolio

Table 69: Shenzhen Neptunus Pharmaceutical Co.,Ltd. Basic Information And Sales Area

Table 70: Shenzhen Neptunus Pharmaceutical Co.,Ltd.. Products Portfolio

Table 71: Global Market Value (USD Million) (2025-2032) By Application

Table 72: Global Market Share (%) By Application (2032)

Table 73: Global Market Value (USD Million) (2025-2032) By Types

Table 74: Global Market Share (%) By Types (2032)

Table 75: Global Market Volume (K) (2025-2032) By Application

Table 76: Global Market Share (%) By Application (2032)

Table 77: Global Market Volume (K) (2025-2032) By Types

Table 78: Global Market Share (%) By Types (2032)

Table 79: Global Naftopidil Tablets Market Value (USD Million) By Region

Table 80: Global Naftopidil Tablets Market Share (%) By Region (2025-2032)

Table 81: North America Market Value (USD Million) (2025-2032) By Country

Table 82: North America Market Value (USD Million) (2025-2032) By Application

Table 83: North America Market Value (USD Million) (2025-2032) By Types

Table 84: Europe Market Value (USD Million) (2025-2032) By Country

Table 85: Europe Market Value (USD Million) (2025-2032) By Application

Table 86: Europe Market Value (USD Million) (2025-2032) By Types

Table 87: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 88: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 89: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 90: South America Market Value (USD Million) (2025-2032) By Country

Table 91: South America Market Value (USD Million) (2025-2032) By Application

Table 92: South America Market Value (USD Million) (2025-2032) By Types

Table 93: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 94: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 95: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 96: Global Naftopidil Tablets Market Volume (K) By Region

Table 97: Global Naftopidil Tablets Market Share (%) By Region (2025-2032)

Table 98: North America Market Volume (K) (2025-2032) By Country

Table 99: North America Market Volume (K) (2025-2032) By Application

Table 100: North America Market Volume (K) (2025-2032) By Types

Table 101: Europe Market Volume (K) (2025-2032) By Country

Table 102: Europe Market Volume (K) (2025-2032) By Application

Table 103: Europe Market Volume (K) (2025-2032) By Types

Table 104: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 105: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 106: Asia Pacific Market Volume (K) (2025-2032) By Types

Table 107: South America Market Volume (K) (2025-2032) By Country

Table 108: South America Market Volume (K) (2025-2032) By Application

Table 109: South America Market Volume (K) (2025-2032) By Types

Table 110: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 111: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 112: Middle East & Africa Market Volume (K) (2025-2032) By Types

Table 113: Research Programs/Design For This Report

Table 114: Key Data Information From Secondary Sources

Table 115: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Naftopidil Tablets Market Overview

Key Market Drivers3 items

Aging demographics and increased BPH prevalence fuel demand in mature markets.

Regulatory approvals for novel formulations (e.g., extended-release tablets) enhance competitive differentiation.

Emerging economies in Asia-Pacific drive volume growth due to rising healthcare accessibility.

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	2.14 billion
Growth rate	CAGR of 7.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Asahi Kasei Corporation; Beijing SL Pharmaceutical Co.,Ltd.; Hubei Qianjiang Pharmaceutical Co.,Ltd.; Shanghai Shyndec Pharmaceutical Co.,Ltd.; Hainan Simcere Pharmaceutical Co.,Ltd.; Bengbu Fengyuan Pharmaceutical Co.,Ltd.; GUIZHOU-EAKAN Pharmaceutical Co.,Ltd.; Tonghua Jitong Medical Co.,Ltd.; Nanjing Meirui Pharma Co.,Ltd.; Shenzhen Neptunus Pharmaceutical Co.,Ltd.
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options